Present law provides coverage can be subject to annual deductibles, coinsurance, copayment provisions established under a health coverage plan and coverage for genetic testing of certain cancer mutations can be subject to applicable evidence-based medical necessity criteria under a health plan.

Proposed law removes provision that genetic testing of certain cancer mutations can be subject to evidence-based medical necessity criteria under a health plan but requires medical necessity for genetic testing of certain cancer mutations based on nationally recognized clinical practice guidelines from institutions like the National Comprehensive Cancer Network, the American Cancer Society, and the Food and Drug Administration labeling.

Effective on July 1, 2022.

(Amends R.S. 22:1028.3(B)(2))